Male Genitourinary Diseases
Male urogenital disorders include a wide range of health problems that affect the male reproductive and urinary systems. These disorders may include, but are not limited to, prostatitis, prostate enlargement, erectile dysfunction, orchitis, epididymitis, priapism, urinary tract infections, and male infertility.
Drug development for these diseases involves several aspects, including etiologic treatment, symptom relief, and prevention of complications. Currently, drug development for male urogenital diseases is focused on the following targets:
- EZH2: EZH2 is a histone methyltransferase that is highly expressed in several cancers and promotes carcinogenesis and malignancy. Tazemetostat, an EZH2 inhibitor, is able to inhibit bladder cancer by activating the immune system, which provides a new direction for the use of epigenetic drugs in bladder cancer treatment.
- KLK2: KLK2 is highly enriched in prostate cancer, and JNJ-78278343, a drug candidate targeting KLK2, is being developed for the treatment of metastatic denervation-resistant prostate cancer (mCRPC).
- PSMA (Prostate Specific Membrane Antigen): PSMA is highly expressed in prostate cancer cells and is a potential target for prostate cancer treatment and imaging. Drugs targeting PSMA, including some novel radioligand therapies, are in development.
- AR (Androgen Receptor): The androgen receptor plays a key role in the development of prostate cancer and is therefore an important target for endocrine therapy. Novel AR antagonists and degraders are being developed to improve therapeutic efficacy.
- PARP (poly ADP-ribose polymerase): PARP inhibitors show potential in the treatment of metastatic denervation-resistant prostate cancer (mCRPC), where they enhance the sensitivity of cancer cells to radiotherapy and certain chemotherapeutic agents by inhibiting DNA repair mechanisms.
- VEGF (vascular endothelial growth factor): VEGF plays a key role in angiogenesis in a variety of tumors, and drugs targeting VEGF, such as bevacizumab, have been used in the treatment of a variety of cancers, including certain genitourinary tumors.
- HER2: HER2 is overexpressed in certain prostate cancer patients, and antibody drug couplers (ADCs) targeting HER2 are in development.
- c-MET: c-MET is a tyrosine kinase receptor that is overexpressed in certain genitourinary tumors and may be a therapeutic target.
Male Genitourinary Diseases Drug Targets
Male Genitourinary Diseases Drug Target Related Products
● Target Proteins
Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized CD152 at 2 μg/ml can bind Anti-CD152 rabbit monoclonal antibody (CSB-RA213310A0HU), the EC50 of human CD152 protein is 27.14-34.82 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized Human IL2RA at 2μg/mL can bind Anti-IL2RA recombinant antibody (CSB-RA011649MA1HU)，the EC50 is 2.463-3.353 ng/mL.
Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody (CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL
Human GH1 protein his/myc tag (CSB-MP009407HU) captured on COOH chip can bind Human GHR protein Fc tag (CSB-MP009411HU) with an affinity constant of 6.1 nM as detected by LSPR Assay.
Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.
Human EGF protein captured on COOH chip can bind Human EGFR protein, his and Myc tag (CSB-MP007479HU) with an affinity constant of 11.9nM as detected by LSPR Assay.
Measured by its binding ability in a functional ELISA. Immobilized Human CD70 at 2 μg/ml can bind Anti-CD70 antibody, the EC50 is 2.414-3.196 ng/mL.
